Cellex
Rome
About Cellex
Cellex, an innovative Small and Medium Enterprise (SME) founded in 2018, specializes in designing and manufacturing advanced bioreactors for cell culture, as well as developing state-of-the-art digital twin software for bioprocesses. Headquartered in Rome, with a subsidiary in Wageningen, Netherlands, Cellex is entering the scale-up phase after securing multiple grants and raising capital from investors. With a solid foothold in the biotech industry, Cellex aims to revolutionize the production of cell-derived drugs, cultivated meat, and tissue engineering through its innovative hardware and software solutions. Key Products • SUSPENCE®®: A patented suspension bioreactor designed for cell culture with high efficiency and reduced operational costs. • BioAxFlow: A multi-tissue bioreactor aimed at tissue engineering and cultivated meat production. • BioDigiTwin: A digital twin software that simulates and optimizes bioprocesses, automating control and enhancing productivity. Markets and Target Segments • Biopharmaceuticals: SUSPENCE® bioreactors to produce vaccines and monoclonal antibodies. • Tissue Engineering: BioAxFlow bioreactors for tissue substitutes, in vitro tissue models, cultivated meat, and other applications. • Digital Twins for Bioprocesses: BioDigiTwin for real-time control and cost optimization of bioprocesses.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $1.1M
- Funding stage: Seed
- Last round: Seed (Oct 2022)
- Website: cellex.it
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/cellex-104929 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.